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Abstract
We conducted a retrospective case-control study of children attending the YaleNew Haven Hospital Premature Infant Primary Care Clinic (YNHH-PIPCC). Subjects
were prematurely born children under 24 months of age cared for at the YNHH-PIPCC
between October 2000 and March 2011. They are eligible to receive monthly passive
respiratory syncytial virus (RSV) immunization with palivizumab during the RSV
season. All cases had laboratory-documented severe RSV disease necessitating hospital
admission or outpatient visit. Controls did not have severe RSV disease during the same
season as their matched case. Controls were matched to the cases by gestational age and
month of birth. Risk of severe RSV disease was estimated using matched ORs and
adjusted for potential confounders with the use of conditional logistic regression. The
hypothesis of this study is that receiving less than all expected doses of palivizumab
reduces the effectiveness of palivizumab in preventing severe RSV disease. Of 299
eligible subjects identified during the study’s 11 RSV seasons (October 2000 through
March 2011), 28 (9%) experienced RSV infections. Of the 28 subjects with RSV
infection, 24 (85.7%) subjects were adherent to the dosing protocol. Severe RSV disease
requiring hospital admission was noted in 15 of 217 (7%) of adherent subjects compared
with 3 of 72 (4%) of non-adherent subjects. Cases of severe RSV disease were more
likely to be Hispanic (61% vs. 39%; p-value: 0.05) than matched controls. There was no
association between adherence to the dosing protocol and hospital admission due to
severe RSV disease. These findings suggest the need for further study of palivizumab
dosing recommendations and factors that may be influencing adverse health events in
premature Hispanic children receiving health care at the YNHH-PIPCC.
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Introduction
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract
morbidity, especially bronchiolitis and pneumonia in children under two years of age. In
the United States, approximately 75,000—125,000 RSV-related infant hospitalizations
occur annually [1]. Annual epidemics of RSV infection occur over a 5-month season
from November through March in temperate climates. Seasonality is a significant factor
in determining the risk of infection. Although RSV infects people of all ages, children
under two years of age are particularly susceptible. Risk factors of severe RSV infection
include preterm birth, chronic lung disease, congenital heart disease, immunodeficiency,
and receipt of immunosuppressive therapy [2].
Premature infants are at high risk for severe RSV infection that often requires
hospitalization. Although there is no existing active immunization for the prevention of
RSV infection, passive immunization with palivizumab (Synagis), a humanized
monoclonal antibody that binds the F-protein of RSV, has been shown to reduce the risk
of RSV hospitalization from 39% to 78% among high-risk infants, depending on the
subsets of the study sample [3]. There was a 39% reduction in RSV hospitalization in
premature infants with bronchopulmonary dysplasia and a 78% reduction in premature
infants with no bronchopulmonary dysplasia. A monthly injection of palivizumab is
recommended to protect high-risk infants throughout the months of each RSV season [4].
The price of a full 5-dose regimen can exceed $8000 (average wholesale price),
depending on the recipient’s body weight [5]. Due to its cost, palivizumab is limited in its
administration to populations at the highest risk for severe RSV illness.
Monthly doses of palivizumab are recommended to maintain a threshold serum
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concentration of anti-RSV antibody, the rationale for which is based largely on previous
studies of palivizumab [3]. These have examined cost-effectiveness of palivizumab
prophylaxis, adherence to monthly palivizumab prophylactic guidelines, and the efficacy
of compliance at reducing RSV infection-related hospitalization in high-risk infants [3, 69]. Little data is available, however, on quantifying the risk of RSV disease in high-risk
patients when they miss monthly doses of palivizumab.
The proposed study aims to evaluate whether incomplete monthly palivizumab
dosing regimens lead to decreased protection from severe RSV disease (i.e. RSV
infection necessitating hospitalization or a hospital outpatient visit) compared with
complete dosing regimens. An incomplete dosing regimen in a premature infant is
defined as one where an infant did not receive all expected palivizumab doses at the time
of a scheduled monthly outpatient visit to the Yale-New Haven Hospital Premature Infant
Primary Care Clinic (YNHH-PIPCC).
Previous studies in premature infants have shown that a complete palivizumab
course offers a reduced risk of hospitalization due to RSV infection of 55% [3], whereas
an incomplete regimen was associated with a significantly higher proportion of
hospitalizations [9]. Accordingly, the hypothesis of this study is an incomplete
palivizumab regimen due to missed doses reduces the effectiveness of palivizumab in
preventing hospitalization due to RSV infection. Such a finding could warrant a reevaluation of the efficiency and cost-effectiveness of current palivizumab dosing
recommendations in high-risk premature infants.
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Methods
Enrollment
We conducted a retrospective case-control medical record review of premature
infants attending the YNHH-PIPCC. Study subjects were premature children who were
cared for at the YNHH-PIPCC between October 2000 and March 2011 and who were
eligible to receive palivizumab according to Pediatric Red Book guidelines.
Study subjects were identified from YNHH-PIPCC database, which contained
names, medical record numbers, and birth dates for all palivizumab eligible patients from
October 2000 through March 2011, a total of eleven RSV seasons.
Case subjects were children under 24 months of age cared for at the YNHH-PIPCC
who were palivizumab eligible (according to Pediatric Red Book guidelines) and were
admitted to the hospital as an inpatient or as an Emergency Department visit due to RSV
infection during the 2000 to 2011 RSV seasons.
Control subjects were children less than 24 months of age cared for at the YNHHPIPCC who were palivizumab eligible (according to Pediatric Red Book guidelines), but
who did not have RSV disease during the same season as their matched case. Controls
were matched to cases by gestational age (±2 weeks from the gestational age of the case)
and season of birth (±1 month of the birth month of the case). The controls were matched
to cases systematically so that preference was given to controls that were within one
week of gestational age of the case.
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Data Collection
Clinical and demographic data for study subjects were obtained from YNHH’s
electronic medical record systems Sunrise Clinical Manager and Logician, including
laboratory data on RSV results from specimens submitted to the clinical virology
laboratory.
Demographic and clinical data included date of birth, race, gender, gestational
age, birth weight, intubation at birth, hospital length of stay after birth, underlying
conditions (congenital heart disease, chronic lung disease, HIV), palivizumab
administration dates, RSV infection dates, and hospital length of stay for RSV infection.
Study personnel created a standardized medical record review form to abstract data from
each subject’s medical record. All information was then entered into Microsoft Access
2007.
According to the American Academy of Pediatrics’ Red Book (2009), indications
for palivizumab eligibility specify that a maximum of 5 monthly doses may be
administered to children younger than 24 months of age with congenital heart disease,
chronic lung disease of prematurity, or a preterm birth at less than 32 weeks gestation.
The protocol recommends that strict adherence to monthly administration be maintained.
Adherence, based strictly on the dosing recommendations, was defined as follows:
Depending on the month of birth, the child received all expected doses and did not miss a
monthly dose. For example, if the first dose was given in December, then it was expected
that the child received four doses through March. Subjects not receiving a full
palivizumab course were categorized as non-adherent. Cases and controls were stratified
by adherence according to whether they received complete dose regimens (received all
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expected doses) or incomplete dose regimens (did not received all expected doses).
Data Analysis
The number of doses of palivizumab received by cases and controls was assessed
through medical record review. Data for palivizumab was stratified by number of doses
received, distinguishing between those who received a complete dose regimen—the
infant received a monthly dose throughout the RSV season—or an incomplete dose
regimen—the infant failed to receive one or more expected monthly doses during the
RSV season. Bivariate analysis using a χ2 test of association was used to examine
associations between subject characteristics and RSV disease status. The risk of severe
RSV disease was estimated directly from matched odds ratios. Conditional logistic
regression was used to adjust for potential confounders. Matched odds ratios measuring
the association of risk factors and RSV infection were calculated with logistic regression
in SAS version 9.2. Tests were conducted at the α level of 0.05 for statistical significance.
P-values equal to or less than 0.05 were considered significant.
Ethical Approval
All study procedures were approved by the Human Investigation Committee at Yale
University.
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Results
A total of 299 study eligible subjects were identified between October 2000 and
March 2011. Overall, 28 (9.4%) RSV infections were identified during the 11 RSV
seasons. Infections occurred during months of October through April, with a majority of

Infections in Sample (n=28)

the infections occurring from December through February (Figure 1).
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Figure 1. RSV infections by month from October 2000 - March 2011
in the study sample.

	
  

This distribution of infections follows the typical pattern of RSV infection in temperate
climates as defined in CDC surveillance reports. Of the 28 infections, 18 (64%) resulted
in hospitalization and 10 (36%) ED visits or clinic visits. Subject characteristics are
shown in Table 1. The majority of children were Black (59.9%) or Hispanic (32.8%).
Overall, 95% had received at least one dose of palivizumab and 226 (75.6%) were found
to be adherent to the dosing protocol. Of the 28 subjects with RSV infection, 24 (85.7%)
subjects were adherent to the dosing protocol. Severe RSV disease requiring hospital
admission was noted in 15 of 217 (7%) of adherent subjects compared with 3 of 72 (4%)
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of non-adherent subjects. This difference was not statistically different (p-value: 0.19).
Ethnicity and congenital heart disease were the only characterizing variables that were
statistically significant in explaining an association with RSV infection (Table 1).

Table 1. Summary of characteristics of the study population by RSV infection.
Characteristic

RSV+
n = 28 (%)

RSVn = 271 (%)

Race/ethnicity
White
Black
Hispanic
Asian
Other

0 (0)
13 (46)
13 (46)
1 (4)
1 (4)

16 (6)
166 (61)
85 (31)
0 (0)
4 (2)

Sex
Male
Female

16 (57)
12 (43)

140 (52)
131 (48)

Mechanical Intubation
Yes
No

4 (14)
24 (86)

18 (7)
253 (93)

Chronic Lung Disease†
Yes
No

13 (46)
15 (54)

107 (39)
164 (61)

Congenital Heart Disease
Yes
No

8 (29)
20 (71)

32 (12)
239 (88)

Non-adherent to dosing protocol*
Yes
No

4 (14)
24 (86)

69 (25)
202 (75)

p
0.02

0.58

0.14

0.47

0.01

0.19

ᶲIncluded: Hemodynamically significant cyanotic or acyanotic congenital heart disease, atrial
septal defect, ventricular septal defect, peripheral pulmonary stenosis, patent ductus arteriosus.
*Definition of adherence: Depending on the month of birth, the child received all expected doses
and did not miss a monthly dose.
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To assess if there were any predictors of non-adherence, non-adherent subjects
were compared with subject characteristics (Table 2). There were no differences in
adherence to dosing for any subject characteristics.

Table 2. Associations between subject characteristics and nonadherent subjects.
Cases
Controls
Nonadherent*
Characteristic
N
n = 18
n = 271
N (%)
Race/ethnicity
White
0
16
16
5 (31)
Black
6
166
172
45 (26)
Hispanic
11
85
96
22 (23)
Asian
0
0
1
0
Other
1
4
5
0
Sex
Male
Female
Mechanical Intubation
Yes
No
Chronic Lung Disease
Yes
No

p
0.52

0.42
8
10

131
140

139
150

42 (30)
30 (20)
0.35

4
14

18
253

22
267

7 (32)
65 (24)
0.40

8
10

107
164

115
174

29 (25)
43 (25)

Congenital Heart
0.52
Diseaseᶲ
Yes
6
32
38
6 (16)
No
12
239
251
66 (26)
ᶲIncluded: Hemodynamically significant cyanotic or acyanotic congenital heart disease, atrial
septal defect, ventricular septal defect, peripheral pulmonary stenosis, patent ductus arteriosus.
*Definition of adherence: Depending on the month of birth, the child received all expected doses
and did not miss a monthly dose.
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Characteristics of cases and controls are shown in Table 3. Of the 299 subjects, a
total of 289 were eligible for the matched analysis. The ten ineligible controls did not
meet matching criteria for gestational age (±2 weeks from the gestational age of the case)
and seasonality of birth (±1 month of the birth month of the case). Cases of RSV were
more likely to be Hispanic (61% vs. 39%; p-value: 0.05) than their matched controls. We
examined the risk of RSV hospitalization for all other race combinations, but did not find
any significant predictors of cases based on these other race combinations.
Table 3. Characteristics of cases and controls.
Cases
Characteristic
n = 18 (%)
Race/ethnicity
All other races
7 (39)
Hispanic
11 (61)

Controls
n = 271 (%)

Matched OR
(95% CI)

186 (69)
85 (31)

Reference
3.46 (1.02, 11.80)

0.05

p

Sex
Female
Male

8 (56)
10 (44)

131 (48)
140 (52)

Reference
1.10 (0.41, 2.91)

0.85

Mechanical Intubation
No
Yes

14 (78)
4 (22)

253 (93)
18 (7)

Reference
3.43 (0.67, 17.69)

0.14

Chronic Lung Disease
No
Yes

10 (56)
8 (44)

164 (61)
107 (39)

Reference
1.40 (0.37, 5.25)

0.61

Congenital Heart Diseaseᶲ
No
Yes

12 (67)
6 (33)

239 (88)
32 (12)

Reference
3.71 (0.95, 14.39)

0.06

Non-adherent to dosing protocol*
No
15 (83)
202 (75)
Reference
Yes
3 (17)
69 (25)
0.92 (0.21, 4.08) 0.91
ᶲIncluded: Hemodynamically significant cyanotic or acyanotic congenital heart disease, atrial
septal defect, ventricular septal defect, peripheral pulmonary stenosis, patent ductus arteriosus.
*Definition of adherence: Depending on the month of birth, the child received all expected doses
and did not miss a monthly dose.
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Matched odds ratios of the association between ethnicity and non-adherence with
hospitalization due to RSV infection are shown in Table 4. When we controlled for
potential confounders, Hispanic subjects continued to be at increased risk of
hospitalization when compared with all other races (OR: 3.47; 95% CI: 1.01-11.84; p value: 0.05). However, we did not find an association between adherence to the dosing
protocol, defined as receiving all expected doses during an RSV season, and
hospitalization due to RSV infection. Non-adherent subjects were no more likely than
adherent subjects to be cases.
Table 4. Multivariate logistic regression model of characteristics associated with hospitalization
due to respiratory syncytial virus infection (N = 289).
Cases
Controls
Matched OR
Characteristic
p
n = 18 (%) n = 271 (%)
(95% CI)
Race/ethnicity
All other races
7 (39)
186 (69)
Reference --Hispanic
11 (61)
85 (31)
3.47 (1.01, 11.84) 0.05
Non-adherent to dosing protocol*
No
15 (83)
202 (75)
Reference --Yes
3 (17)
69 (25)
1.02 (0.23, 4.50) 0.98
*Definition of adherence: Depending on the month of birth, the child received all expected doses
and did not miss a monthly dose.

In the bivariate analysis, the test association between Hispanic ethnicity and study
characteristics identified two statistically significant associations. First, being Hispanic
was associated with having congenital heart disease (p-value: 0.03). Additionally, being
Hispanic was associated with hospitalization due to RSV infection (p-value: 0.01).
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Discussion
This case-control study examines the risk of severe RSV disease due to a failure
in receiving all expected palivizumab doses during an RSV season. Non-adherence to the
recommended dosing protocol, defined as failing to receive all expected doses throughout
an RSV season, was found to have no association with hospitalization due to RSV
infection. Hispanic children were found to be at increased risk for hospitalization due to
RSV infection (OR: 3.47, 95% CI: 1.01-11.84) when controlling for potential
confounders. Based on these results, efforts to maintain complete adherence to the dosing
protocol may not be necessary. Missing one of the expected doses during the RSV season
may not put a child at increased risk of RSV hospitalization. Optimal palivizumab dosing
for the prevention of RSV infection must take into account the increased risk of severe
RSV disease in Hispanic children.
The lack of a significant association between missing one or more doses of
palivizumab and being hospitalized due to RSV infection may be partially explained by
palivizumab titer in children who received the drug. Monthly doses of palivizumab are
recommended to maintain a threshold serum concentration of anti-RSV antibody. The
target for threshold serum concentration is 40 µg/ml, which was derived from preclinical
data in rats. Rats maintaining levels greater than this threshold showed a 99% reduction
in pulmonary RSV. The IMpact RSV-Group reported data on serum concentration of
palivizumab in premature infants as part of the palivizumab approval study [3]. The data
suggest the trend of a cumulative effect of serum concentration through monthly dosing
at 15mg/kg concentration. If a child missed one dose but maintained a serum
concentration level above the threshold level of anti-RSV antibody, then the child may
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still be protected against viral insult. Another possibility is that children who were
adherent were at higher risk for severe disease than children who were non-adherent due
to factors that were not detected in our analysis.
An interesting finding in the current study was that Hispanic children were more
likely to have congenital heart disease and more likely to be hospitalized with severe
RSV disease when compared with all other ethnicities. Although congenital heart disease
was not found to be associated with RSV hospitalization, the increased risk of congenital
heart disease in Hispanics may be a factor in explaining the high proportion of RSV
hospitalization among this group of children.
This study was not without limitations. Subjects were enrolled from a single
healthcare center, so there was a relatively small sample size with only 28 subjects
infected with RSV and 18 hospitalizations due to RSV in 11 seasons. However, study
personnel were able to capture all eligible children who attended the YNHH-PIPCC.
Additionally, data on palivizumab administration for children at YNHH was thoroughly
recorded from the first RSV season that the drug was administered. YNHH-PIPCC
consistently administered palivizumab, as can be seen in the high proportion (75%) of
children receiving a full course of the prophylactic drug. This may partially explain the
low number of RSV infections in the sample.
Palivizumab was developed to prevent RSV infection, not necessarily to prevent
RSV hospitalization. The reported results restricted the analysis to children hospitalized
with RSV disease (n=18). However, including all 28 RSV-infected children in the
analysis did not significantly change results. Limiting cases to children hospitalized with
RSV infection was necessary to capture only severe RSV infections. Because children
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may have acquired RSV infection without seeking or acquiring medical care, estimated
associations between RSV infection and characteristics of subjects would have been
biased had we not separated the most severe RSV cases from the controls.
The findings of this study prompt a continued investigation of the effectiveness of
palivizumab dosing recommendations. Capturing more cases by expansion to additional
study sites is necessary to improve precision in identifying associations between subject
characteristics and clinical outcomes. With these additional data, palivizumab-eligible
children can be stratified based on every dose received. The effectiveness of each dose
can be directly estimated. Furthermore, a greater distribution of the ethnicities enrolled in
this study would be beneficial for comparing risk factors for severe RSV disease. To
examine if palivizumab titer influences the risk of RSV infection, a laboratory component
could be designed to measure serum concentrations for infants receiving palivizumab.
This information could be related to the risk of RSV infection among adherent and nonadherent dosing groups receiving various numbers of doses throughout an RSV season.
Preterm children are at increased risk of respiratory syncytial virus infection. This
retrospective study shows palivizumab dosing adherence over 11 RSV seasons at the
Yale-New Haven Hospital Premature Infant Primary Care Clinic and relates it to the risk
of hospitalization due to RSV. No association was found between RSV hospitalization
and dosing adherence. However, Hispanic children were found to be at increased risk of
RSV hospitalization and congenital heart disease. This finding should prompt further
exploration of factors that may be influencing adverse health events in Hispanic preterm
infants receiving health care at the Yale-New Haven Hospital Premature Infant Primary
Care Clinic.
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